1.2Two carbons before the carbonyl
Setting m to 2 and using hydrogen at both substituent positions on each spacer carbon gives a —CH₂—CH₂—C(=O)— segment. The two methylene units provide additional separation between the ring system and the carbonyl.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
Setting m to 2 and using hydrogen at both substituent positions on each spacer carbon gives a —CH₂—CH₂—C(=O)— segment. The two methylene units provide additional separation between the ring system and the carbonyl.
Setting n to 12 and using hydrogen at all four substituent positions in each repeat gives a segment of twelve —O—CH₂—CH₂— units. The flexible segment separates the terminal group from the carbonyl, and its ether oxygens accept hydrogen bonds from water.
With m set to 1 and R1B set to hydrogen, the spacer is a —CHF— unit. This unit maintains a one-carbon connection to the carbonyl and introduces a polar carbon–fluorine bond.
With m set to 1 and R1A set to hydrogen, the spacer carbon connects the ring system to the carbonyl and bears a cyclopropyl branch. The three-membered ring provides a compact hydrocarbon branch whose internal bond geometry is fixed by ring closure.
With n set to 1, all four repeat substituents set to hydrogen, and p set to 1, the terminal segment is —C(=O)—O—CH₂—CH₂—O—phenyl. The terminal ether oxygen connects the flexible chain to a rigid aromatic ring.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A substituted pyridotriazine reference panel retains the same ring substitutions across all members and uses straight-chain C4, C8, and C12 terminal alkyl groups. Each reference occupies a separate vial, and a fourth vial contains a mixture at equal molar concentrations. In an analytical chemistry training lab, students inject the individual references and then assign peaks in the mixture by matching retention times under the same reversed-phase gradient.
An oxetan-3-yl group replaces a cyclobutyl group at R1G, with p set to 1 so a terminal oxygen connects the side chain to ring carbon 3. The two compounds use m = 1 and n = 0 and share the same remaining substituents. A shake-flask assay quantifies the distribution of each compound between octanol and aqueous buffer at the same pH.
A terminal methoxy substituent on a C4 alkyl R1G group is replaced with an N-linked methyl carbamate, —NHCOOCH3. Both members of the pair use m = 1, n = 0, and p = 1 with identical ring substitutions. An equilibrium solubility assay agitates each solid in the same buffer, removes suspended material by centrifugation, and measures dissolved compound by liquid chromatography.
A matched series uses n values of 4, 5, 6, 8, and 10, with m = 0, p = 1, and a methyl group at R1G. Every repeat unit has hydrogen at R1C, R1D, R1E, and R1F, and all five compounds share the same ring substitutions. Reversed-phase liquid chromatography measures retention for each compound using a single gradient and injection concentration.
A flow-through dissolution cell holds a compressed tablet containing a substituted pyridotriazine salt between an inlet bead bed and an outlet filter. A pump supplies temperature-controlled buffer at a fixed flow rate, and a fraction collector receives the filtered effluent at fixed intervals. Liquid chromatography measures the compound concentration in each fraction, and concentration multiplied by fraction volume gives the amount released during that interval.
A liquid handler dispenses one substituted pyridotriazine stock solution into a sealed plate containing buffers at pH 5, 7, and 9, with separate wells for each sampling time. The plate incubates at 37 °C, and the handler transfers aliquots into chilled acidified acetonitrile at 0, 2, 8, and 24 hours. Liquid chromatography with mass spectrometry measures the parent compound, and software reports its peak area relative to the corresponding zero-hour sample after normalization to an internal standard.
Setting m and n to 0, p to 1, and R1G to ethyl gives a —C(=O)—O—CH₂—CH₃ substituent. The carbonyl carbon bonds directly to the ring system.
Setting p to 1 places an oxygen between the final repeat carbon and a methyl R1G group. With n set to 1 and all four repeat substituents set to hydrogen, the chain ends in —O—CH₂—CH₂—O—CH₃.
In a single repeat unit, setting R1C to methyl and R1D, R1E, and R1F to hydrogen gives —O—CH(CH₃)—CH₂—. The methyl branch sits on the carbon directly bonded to the repeat oxygen.
Oxetan-3-yl supplies a four-membered terminal ring with one oxygen and three carbons. The side chain attaches at carbon 3, opposite the ring oxygen.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Alk1 and Alk2 independently represent divalent C1–C3 alkylen radicals;A · US 7,192,953 B2 · claim 10
A represents a primary, secondary or tertiary amino group or a group —R5, —OR5, wherein R5 is a substituted or unsubstituted C1–C6 alkyl, C2–C6 alkenyl, C2–C6 alkynyl, cycloalkyl, aryl, heterocyclyl, C1–C3 alkyl-O—C1–C3 alkyl, C1–C3 alkyl-S—C1–C3 alkyl, cycloalkyl(C1–C3 alkyl)-, heterocyclic(C1–C3 alkyl, aryl(C1–C3 alkyl)-, or R1R2N—C1–C3 alkyl group wherein R1 represents hydrogen or C1–C3 alkyl and R2 represents C1–C3 alkyl, or R1R2N— represents a cyclic amino group.A · US 7,192,953 B2 · ¶ 30
Cy2 is cyclohexyl or tetrahydropyranyl, each optionally substituted with one or more groups selected from halo and halo(C1-C3)alkyl;B · US 2016/0122345 A1 · claim 1
X represents —O—, —S—, —S(O)—, —S(O2)—, —C(═O)—, —NH—, —NR7— where R7 is C1–C3 alkyl; and wherein Alk1 and Alk2 and Z when other than hydrogen, independently are optionally substituted by (C1–C3)alkyl, (C2–C3)alkenyl, or (C2–C3)alkynyl, phenyl, optionally substituted by (C1–C3)alkyl, (C1–C3) alkoxy, halo, nitro, amino, mono- or di-(C1–C33) alkylamino, cyano or trifluoromethyl; monocyclic 5 or 6-membered heterocyclic, optionally substituted by (C1–C3)alkyl, (C1–C3 alkoxy, haloA · US 7,192,953 B2 · claim 10
A compound of the Formula: or a pharmaceutically acceptable salt thereof, wherein R2 is (C1-C3)alkyl, hydroxy(C1-C3)alkyl, halo(C1-C3)alkyl, benzyl, (C1-C3)alkoxy(C1-C3)alkyl, tetrahydropyranyl, or —CH2-tetrahydropyranyl;B · US 2016/0122345 A1 · claim 1
An empty cell means only that no passage was reproduced there.
Accordingly there is a continuing need in the art for alternative antibacterial agents, especially those which have mechanisms of action fundamentally different from the known classes, and/or which are effective against the causative organisms of community acquired respiratory infections, and/or which are selective in their pharmacological activity, thus reducing risk of unwanted side effects.A · US 7,192,953 B2 · ¶ 4
Although it may be of interest to establish the mechanism of action of the compounds with which the invention is concerned, it is their ability to inhibit bacterial growth that makes them useful.A · US 7,192,953 B2 · ¶ 7
The present invention is directed to novel retinoic acid receptor-related orphan receptor gamma (“RORγ” or “ROR-gamma”) inhibitors, processes for their preparation, pharmaceutical compositions containing these inhibitors, and their use in the treatment of inflammatory, metabolic, autoimmune and other diseases mediated by RORγ.B · US 2016/0122345 A1 · ¶ 2
patent.fyi, US 2026/0356836 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356836/, SHA-256 c29f391f66c6f6fcef8c20eebc85d4d3dca4252dfe1b8e9cf469a546781dbe55